Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTXR NASDAQ:EVOK NASDAQ:ITRM NASDAQ:JAGX NASDAQ:MBRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$0.61+0.7%$0.64$0.48▼$2.48$16.71M1.03593,558 shs338,047 shsEVOKEvoke Pharma$11.00+0.4%$10.90$2.28▼$11.00$18.92M-0.15983,927 shs47,100 shsITRMIterum Therapeutics$0.03$0.03$0.03▼$1.42$1.60M2.964.85 million shsN/AJAGXJaguar Animal Health$3.04+1.3%$4.53$2.12▼$97.65$1.82M-0.0999,228 shs47,776 shsMBRXMoleculin Biotech$2.69-3.6%$2.58$1.79▼$24.00$14.37M1.77333,207 shs672,429 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals+4.48%+7.95%-7.70%-28.30%-61.98%EVOKEvoke Pharma0.00%0.00%0.00%0.00%+323.08%ITRMIterum Therapeutics0.00%0.00%0.00%-5.36%-96.98%JAGXJaguar Animal Health+1.35%+17.19%-15.49%-78.89%-96.60%MBRXMoleculin Biotech-21.85%+1.45%0.00%+25.11%-63.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$0.61+0.7%$0.64$0.48▼$2.48$16.71M1.03593,558 shs338,047 shsEVOKEvoke Pharma$11.00+0.4%$10.90$2.28▼$11.00$18.92M-0.15983,927 shs47,100 shsITRMIterum Therapeutics$0.03$0.03$0.03▼$1.42$1.60M2.964.85 million shsN/AJAGXJaguar Animal Health$3.04+1.3%$4.53$2.12▼$97.65$1.82M-0.0999,228 shs47,776 shsMBRXMoleculin Biotech$2.69-3.6%$2.58$1.79▼$24.00$14.37M1.77333,207 shs672,429 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals+4.48%+7.95%-7.70%-28.30%-61.98%EVOKEvoke Pharma0.00%0.00%0.00%0.00%+323.08%ITRMIterum Therapeutics0.00%0.00%0.00%-5.36%-96.98%JAGXJaguar Animal Health+1.35%+17.19%-15.49%-78.89%-96.60%MBRXMoleculin Biotech-21.85%+1.45%0.00%+25.11%-63.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXRCitius Pharmaceuticals 2.25Hold$5.00721.15% UpsideEVOKEvoke Pharma 1.50ReduceN/AN/AITRMIterum Therapeutics 1.67ReduceN/AN/AJAGXJaguar Animal Health 1.00SellN/AN/AMBRXMoleculin Biotech 2.33Hold$22.00717.84% UpsideCurrent Analyst Ratings BreakdownLatest EVOK, ITRM, JAGX, MBRX, and CTXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026CTXRCitius Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/19/2026CTXRCitius Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/18/2026CTXRCitius Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.004/21/2026JAGXJaguar Animal Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026MBRXMoleculin Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXRCitius PharmaceuticalsN/AN/AN/AN/A$4.29 per shareN/AEVOKEvoke Pharma$10.25M1.85N/AN/A$4.74 per share2.32ITRMIterum Therapeutics$390K4.10N/AN/A($0.15) per share-0.20JAGXJaguar Animal Health$11.51M0.16N/AN/A($106.11) per share-0.03MBRXMoleculin BiotechN/AN/AN/AN/A$4.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXRCitius Pharmaceuticals-$37.43M-$2.13N/AN/AN/AN/A-61.09%-35.36%8/11/2026 (Estimated)EVOKEvoke Pharma-$5.35M-$2.07N/AN/AN/A-36.23%-101.40%-31.86%N/AITRMIterum Therapeutics-$24.77M-$0.75N/AN/AN/AN/AN/A-65.54%N/AJAGXJaguar Animal Health-$53.43M-$591.92N/AN/AN/A-169.04%-1,194.94%-115.55%8/13/2026 (Estimated)MBRXMoleculin Biotech-$33.56M-$17.98N/AN/AN/AN/AN/A-70.93%8/11/2026 (Estimated)Latest EVOK, ITRM, JAGX, MBRX, and CTXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026JAGXJaguar Animal Health-$149.10-$13.60+$135.50-$13.60$4.21 million$20.27 million5/15/2026Q2 2026CTXRCitius Pharmaceuticals-$0.2808-$0.95-$0.6693-$0.95$10.23 millionN/A5/14/2026Q1 2026MBRXMoleculin Biotech-$2.3333-$3.54-$1.2067-$3.54N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AJAGXJaguar Animal HealthN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXRCitius PharmaceuticalsN/A0.580.16EVOKEvoke PharmaN/A1.271.22ITRMIterum TherapeuticsN/A2.131.96JAGXJaguar Animal Health4.080.500.30MBRXMoleculin BiotechN/A1.381.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXRCitius Pharmaceuticals16.88%EVOKEvoke PharmaN/AITRMIterum Therapeutics9.21%JAGXJaguar Animal Health12.04%MBRXMoleculin Biotech15.52%Insider OwnershipCompanyInsider OwnershipCTXRCitius Pharmaceuticals4.99%EVOKEvoke Pharma2.29%ITRMIterum Therapeutics2.00%JAGXJaguar Animal Health2.00%MBRXMoleculin Biotech1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXRCitius Pharmaceuticals2027.45 million26.08 millionOptionableEVOKEvoke Pharma41.72 million1.68 millionNot OptionableITRMIterum Therapeutics1053.29 million52.23 millionNot OptionableJAGXJaguar Animal Health50600,000591,000No DataMBRXMoleculin Biotech205.34 million5.28 millionNot OptionableEVOK, ITRM, JAGX, MBRX, and CTXR HeadlinesRecent News About These CompaniesMBRX stock drops 25% as Moleculin Biotech's interim cancer trial data falls short of significanceJuly 1 at 2:00 PM | msn.comWhy is Moleculin Stock Falling Today?June 30 at 3:01 PM | benzinga.comMoleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than ControlJune 30 at 8:30 AM | globenewswire.comMoleculin Biotech Insider Trading Activity | NASDAQ:MBRX | BenzingaJune 25, 2026 | benzinga.comIndependent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AMLJune 5, 2026 | globenewswire.comMoleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” SegmentJune 4, 2026 | globenewswire.comMoleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline LimitsMay 29, 2026 | globenewswire.comMoleculin Biotech Releases Updated Investor Information PresentationMay 26, 2026 | tipranks.comMoleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for AnnamycinMay 21, 2026 | globenewswire.comMoleculin Biotech Reports Promising Early Results in MIRACLE Trial for AML Treatment with 40% Composite Complete Remission RateMay 15, 2026 | quiverquant.comQMoleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE TrialMay 15, 2026 | globenewswire.comMoleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical BenchmarksMay 13, 2026 | globenewswire.comIndependent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline LimitsMay 12, 2026 | globenewswire.comMoleculin Biotech Secures Hong Kong Patent for Annamycin Method Ahead of Phase 3 Clinical Data ReleaseMay 8, 2026 | quiverquant.comQMoleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of AnnamycinMay 8, 2026 | globenewswire.comMoleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026April 24, 2026 | markets.businessinsider.comMoleculin Biotech, Inc. Reports Promising Preclinical Results for Annamycin in Pancreatic Cancer TreatmentApril 23, 2026 | quiverquant.comQMoleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026April 23, 2026 | globenewswire.comMoleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual MeetingApril 21, 2026 | globenewswire.comMoleculin Biotech Stockholders Approve Warrant Share IssuanceApril 15, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVOK, ITRM, JAGX, MBRX, and CTXR Company DescriptionsCitius Pharmaceuticals NASDAQ:CTXR$0.61 +0.00 (+0.73%) Closing price 04:00 PM EasternExtended Trading$0.61 0.00 (-0.15%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Evoke Pharma NASDAQ:EVOKEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Iterum Therapeutics NASDAQ:ITRM$0.03 0.00 (0.00%) As of 06/30/2026Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Jaguar Animal Health NASDAQ:JAGX$3.04 +0.04 (+1.33%) Closing price 04:00 PM EasternExtended Trading$3.00 -0.04 (-1.48%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Moleculin Biotech NASDAQ:MBRX$2.69 -0.10 (-3.58%) Closing price 04:00 PM EasternExtended Trading$2.62 -0.06 (-2.42%) As of 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks AirJoule Unveils Prime System, Clearing Path to Commercialization Comcast’s NBCUniversal Split Puts Broadband Back in Focus Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets Ouster Is Breaking Out as a Physical AI Leader: Here's What's Driving the Move Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
